|
IMID
|
IMID occurred after the index date
|
Excluding those with IMID within 3 months after the index date
|
|---|
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
|---|
|
Acute anterior uveitis
|
9.07 (7.52–10.94)e
|
< 0.01
|
10.98 (9.10–13.25)e
|
< 0.01
|
|
Psoriasis
|
1.69 (1.24–2.29)f
|
< 0.01
|
1.41 (1.01–1.96)e
|
0.04
|
|
Inflammatory bowel disease
|
2.11 (0.39–11.48)d
|
0.39
|
0.35 (0.06–2.06)e
|
0.24
|
|
Crohn’s disease
|
8.01 (1.79–35.79)c
|
0.01
|
2.74 (0.31–24.52)b
|
0.37
|
|
Ulcerative colitis
|
0.33 (0.05–2.37)f
|
0.27
|
0.33 (0.05–2.37)f
|
0.27
|
|
Systemic lupus erythematosus
|
0.93 (0.49–1.79)f
|
0.84
|
0.81 (0.40–1.64)f
|
0.56
|
|
Sjögren’s syndrome
|
2.05 (1.39–3.01)f
|
< 0.01
|
1.29 (0.84–1.99)f
|
0.25
|
|
Rheumatoid arthritis
|
0.70 (0.50–0.99)f
|
0.04
|
0.46 (0.33–0.65)e
|
< 0.01
|
|
Systemic sclerosis
|
1.65 (0.45–6.02)e
|
0.45
|
1.65 (0.45–6.02)e
|
0.45
|
|
Dermatomyositis
|
0.95 (0.22–4.02)f
|
0.94
|
0.29 (0.04–1.99)f
|
0.21
|
|
Polymyositis
|
7.96 (0.97–65.56)f
|
0.05
|
7.96 (0.97–65.56)f
|
0.05
|
|
Thromboangiitis obliterans
|
16.62 (2.78–99.52)a
|
< 0.01
|
16.62 (2.78–99.52)a
|
< 0.01
|
|
Behcet’s disease
|
20.37 (5.54–74.85)f
|
< 0.01
|
26.20 (6.27–109.45)e
|
< 0.01
|
|
Pemphigus
|
0.97 (0.07–13.48)d
|
0.98
|
0.97 (0.07–13.48)d
|
0.98
|
|
Sarcoidosis
|
5.39 (2.15–13.48)f
|
< 0.01
|
6.09 (2.38–15.58)f
|
< 0.01
|
|
Vitiligo
|
1.55 (0.73–3.32)f
|
0.26
|
1.42 (0.63–3.22)f
|
0.40
|
- Abbreviations: AS ankylosing spondylitis, IMID immune-mediated inflammatory disease, HR hazard ratio, CI confidence interval
- Adjusted variables: anone; bage; cage and sex; dage, sex and medications; eage, sex, medications and the frequency of visits; fage, sex, medications, the frequency of visits and Charlson comorbidity index. Models with the least Akaike information criterion were selected
